Commentary|Articles|February 11, 2026

Kidney Cancer Experts Preview Practice-Shaping Trials Taking Center Stage at ASCO GU 2026

Fact checked by: Chris Ryan

Experts highlight key RCC studies at the 2026 Genitourinary Cancers Symposium, with a focus on combination-based strategies and patient-reported outcomes.

As anticipation builds for the 2026 Genitourinary (GU) Cancers Symposium, OncLive® asked leading kidney cancer specialists to share the renal cell carcinoma (RCC) research topics and abstracts they are most eager to see at this year’s meeting, including late-phase updates that may refine adjuvant strategies and reshape post–PD-(L)1 treatment sequencing.

Related to this article

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.

October 7th, 2026

September Roundup of FDA Approvals in Oncology: 8 Decisions to Know

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.

Myeloma | Image Credit: Tongpoon - stock.adobe.com

October 7th, 2026

Etentamig, Iberdomide, and Long-Term PERSEUS Data Headline Key Myeloma Findings From IMS 2026

Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.

September 30th, 2026

Breast Cancer Experts Highlight Abstracts to Watch at ESMO 2026

Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.

Iberdomide Plus Daratumumab/Dexamethasone in Multiple Myeloma | Image Credit: © LELISAT - stock.adobe.com

September 26th, 2026

Iberdomide Plus Daratumumab/Dexamethasone Improves MRD-Negative CR vs DVd in Relapsed/Refractory Myeloma

The first MRD data from the phase 3 EXCALIBER-RRMM trial support iberdomide-based triplet therapy as early as first relapse, with PFS follow-up ongoing.

D-VRd in Transplant-Eligible Newly Diagnosed Myeloma | Image Credit: © Nicat - stock.adobe.com

September 26th, 2026

Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma

After nearly 7 years of follow-up, daratumumab added to VRd continued to improve PFS, PFS2, and sustained MRD negativity in transplant-eligible myeloma.

The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.

September 26th, 2026

The OncFive: Top Oncology Articles for the Week of 9/20/2026

The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.

September 26th, 2026

OncLive Weekly News Quiz (9/26/2026): Did You Catch the Latest RCC, CCA, Sarcoma, and Bladder Cancer News?

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

September 25th, 2026

Etentamig Improves Response and PFS vs Standard Therapies in Triple-Class Exposed Relapsed/Refractory Myeloma

Monthly etentamig significantly improved response and PFS over standard available therapies in the phase 3 CERVINO trial, with low rates of high-grade CRS.